pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
PUBLIC COMPANY
save

$ORKAOruka Therapeutics, Inc.

$ORKA102.86+7.12%
Menlo Park, CA, USupdated 11d ago
Website ↗SEC EDGAR ↗Yahoo Finance ↗
community read0 votes
pipeline
1
marketed
0
phase 3
0
catalysts ytd
2
approvals ytd
0
recalls ytd
0

Pipeline(1)

pipeline depth1 products
Phase 2: 1
1Phase 2
Phase 2
ORKA-001
Plaque Psoriasis (Psoriasis Vulgaris)

📅 Upcoming

no upcoming catalysts on record

🕒 Recent(90d)

nothing in the last 90 days
view all catalysts →

Active trials

  • phase2ORKA-002 Versus Placebo in Participants With Moderate-to-Severe Hidradenitis Suppurativarecruitingn=200
  • phase1ORKA-002-211 A Phase I Study to Evaluate ORKA-002 in Healthy Volunteers Following A Single Dosecompletedn=24
  • phase2An Open-Label Extension Study of ORKA-001 in Participants With Plaque Psoriasisrecruitingn=240
  • phase2Dose Ranging Study of ORKA-001 in Patients With Moderate-to-Severe Plaque Psoriasisactive not recruitingn=160
  • phase2ORKA-001 Versus Placebo in Patients With Moderate-to-Severe Plaque Psoriasisactive not recruitingn=80
  • phase2Dose Ranging Study of ORKA-002 in Patients With Moderate-to-Severe Plaque Psoriasisrecruitingn=160
  • phase1ORKA-001 in Healthy Volunteerscompletedn=24
🐶 Hiring Signal
No open roles indexed yet — view Oruka Therapeutics, Inc. jobs →

News

  • Biotech builder Paragon imports Apogee's top brass after AbbVie buyout
    It’s been a busy morning for Paragon Labs. In addition to bringing over much of the leadership team from AbbVie-acquired Apogee Therapeutics, Paragon has overseen a reverse merger to take its hyper…
    fiercebiotech · 1mo ago
  • 6 immunology targets to sustain a mammoth I&I market
    Johnson & Johnson, Pfizer, Argenx and more are unlocking new immunology targets and looking to improve on existing ones in an attempt to catch some of the magic brought about by AbbVie’s Humira and…
    biospace · 1mo ago
  • Oruka surges as long-acting psoriasis drug shows early promise
    A therapy that works similarly to AbbVie’s blockbuster Skyrizi appeared more potent in a mid-stage trial and has the potential to be dosed less frequently.
    biopharma_dive · 6mo ago
  • STAT+: Oruka’s long-acting psoriasis therapy posts strong results in mid-stage study
    A long-acting injectable treatment for plaque psoriasis helped 63% of patients achieve complete skin clearance in a clinical trial, its maker, Oruka Therapeutics, reported.
    stat · 6mo ago
identifiers
ticker
$ORKA
SEC CIK
0000907654
country
US
source
sec_tickers
top tags
Immunology1
mentioned in
4news items
entity-linker matched
Data sources
SEC EDGAR
last refreshed 2m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?